Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference - WMBB News 13 - The Panhandle's News Leader

Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference

  • What's Going Around

  • Wednesday, May 15 2013 11:45 AM EDT2013-05-15 15:45:20 GMT
    While cold and flu season is widely discussed, pneumonia season is quickly gaining the spotlight. One in 20 dies from the lung disease each year, and it's what's going around this week. What is pneumonia? Pneumonia
    While cold and flu season is widely discussed, pneumonia season is quickly gaining the spotlight. One in 20 dies from the lung disease each year, and it's what's going around this week.

  • Wednesday, May 8 2013 9:06 AM EDT2013-05-08 13:06:30 GMT
    We all have our aches in our bellies and backs from time to time, but these pains can also be signs of gallstones. Dr. Hatem Mourad from Coastal Urgent Care and Family Medicine warns that gallstones are
    Dr. Hatem Mourad from Coastal Urgent Care and Family Medicine warns that gallstones are what's going around.

  • Medical Central is the source for local doctors to advertise their businesses, as well as provide clients and viewers with valuable information on their fields of study.
    •   

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Sangamo BioSciences, Inc.

RICHMOND, Calif., Feb. 27, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:40 am ET on Wednesday, March 6, 2013, at the 33rd Annual Cowen and Company Health Care Conference which will be held in Boston.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

©2012 PR Newswire. All Rights Reserved.